By narrowing the scope to MYC-related metabolic regulation, this offers a more targeted approach to therapeutic development, potentially leading to the identification of biomarkers and synthetic lethality targets to disrupt MYC-driven metabolic reprogramming in cancer. The gene discussed is MYC; the disease is cancer.